Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2019 Jan-Dec:18:2325958219841908.
doi: 10.1177/2325958219841908.

Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs

Esther Muya  1 , Appolinary Kamuhabwa  1
Affiliations
Comparative Study

Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs

Esther Muya et al. J Int Assoc Provid AIDS Care. 2019 Jan-Dec.

Abstract

Objective: To assess prevalence of hyperlipidemia in patients receiving lopinavir boosted with ritonavir (LPV/r) and atazanavir boosted with ritonavir (ATV/r) antiretroviral drugs.

Methods: HIV-infected patients (300) were recruited in the study between December 2015 and April 2016. Lipid profile including triglycerides (TG), high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol (LDL-C) were assessed.

Results: Prevalence of derangement in TG was 71.0% in patients using LPV/r compared to 44% in those using ATV/r ( P = .01). Use of LPV/r was independently associated with increased total cholesterol (TC; P = .001) and TG ( P = .0003). Females had raised levels of TC compared to males ( P = .00008). Body mass index of ≥ 25 kg/m2 was also associated with raised TC ( P = .002) and LDL-C ( P = .006).

Conclusion: LPV/r was significantly associated with lipid derangements, indicating the need to regularly monitor lipid profile in patients using LPV/r.

Keywords: ARVs; ATV/r; HIV; LPV/r; hyperlipidemia.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Kagaruki GB, Mayige MT, Ngadaya ES, et al. Magnitude and risk factors of non-communicable diseases among people living with HIV in Tanzania: a cross sectional study from Mbeya and Dar es Salaam regions. BMC Public Health. 2014;14:904. - PMC - PubMed
    1. Husain NEO, Ahmed MH. Managing dyslipidemia in HIV/AIDS patients: challenges and solutions. HIV/AIDS (Auckland, NZ). 2015;7:1–10. - PMC - PubMed
    1. Eliseo A, Morgello ES, Klotman ME, et al. Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol. 2008;172(4):1100–1111. - PMC - PubMed
    1. Rabkin M, Nishtar S. Scaling up chronic care systems: leveraging HIV programs to support non-communicable diseases services. J Acquir Immune Defic Syndr. 2011;57(Suppl 2):S87–S90. - PubMed
    1. Hirschhorn LR, Kaaya SF, Garrity PS, et al. Cancer and the ‘other’ non-communicable chronic diseases in older people living with HIV/AIDS in resource-limited settings: a challenge to success. AIDS. 2012;26(Suppl 1):S65–S75. - PubMed

Publication types

MeSH terms